Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Nautilus Biotechnology Inc (NAUT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: NAUT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.27% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 110.27M USD | Price to earnings Ratio - | 1Y Target Price 1.88 |
Price to earnings Ratio - | 1Y Target Price 1.88 | ||
Volume (30-day avg) 149265 | Beta 1.07 | 52 Weeks Range 0.82 - 3.09 | Updated Date 04/1/2025 |
52 Weeks Range 0.82 - 3.09 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -18.57% | Return on Equity (TTM) -29.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10863991 | Price to Sales(TTM) - |
Enterprise Value 10863991 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2 | Shares Outstanding 126148000 | Shares Floating 46630782 |
Shares Outstanding 126148000 | Shares Floating 46630782 | ||
Percent Insiders 33.37 | Percent Institutions 49.62 |
Analyst Ratings
Rating 3.6 | Target Price 3.44 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 2 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Nautilus Biotechnology Inc
Company Overview
History and Background
Nautilus Biotechnology Inc. was founded in 2016. The company is focused on developing a single-molecule protein analysis platform for biomedical research and drug discovery. It went public through a SPAC merger with Arya Sciences Acquisition Corp III in 2021.
Core Business Areas
- Protein Analysis Platform Development: Development of a platform for analyzing and quantifying the proteome, enabling deeper insights into biological processes and disease mechanisms.
Leadership and Structure
Suzi Turner is the CEO. The company has a typical biotech organizational structure with departments focused on research, development, engineering, and commercialization.
Top Products and Market Share
Key Offerings
- Nautilus Proteome Analysis Platform (In Development): Nautilus is developing a platform for proteomic analysis. It's not yet commercially available, therefore there is no market share or user data at this point. Competitors will be companies like SomaLogic and Olink in the proteomics space. They are not generating any revenue from this product right now, but they are investing to complete development.
Market Dynamics
Industry Overview
The proteomics market is growing rapidly, driven by the increasing need for comprehensive protein analysis in drug discovery, diagnostics, and personalized medicine. The market is competitive, with several established players and emerging companies.
Positioning
Nautilus aims to disrupt the proteomics market with its single-molecule analysis platform, offering higher sensitivity and throughput than existing technologies. It's positioned as an innovative technology developer, but is not yet generating revenues.
Total Addressable Market (TAM)
The total addressable market for proteomics is estimated to be in the billions of dollars and is expected to grow significantly in the coming years. Nautilus Biotechnology Inc. is positioning itself as a company with a novel technology that will allow the company to expand and gain significant revenue in this space.
Upturn SWOT Analysis
Strengths
- Novel Technology
- Experienced Leadership Team
- Strong Intellectual Property Portfolio
- Potential for High Sensitivity and Throughput
Weaknesses
- Pre-Revenue Stage
- Technology Development Risk
- High Cash Burn Rate
- Reliance on Future Funding
Opportunities
- Partnerships with Pharmaceutical Companies
- Expanding Applications of Proteomics
- Growing Demand for Personalized Medicine
- Advancements in Data Analytics
Threats
- Competition from Established Proteomics Companies
- Technological Obsolescence
- Regulatory Hurdles
- Economic Downturn
Competitors and Market Share
Key Competitors
- SomaLogic (SLGC)
- Olink Holding AB (OLK)
- Quanterix Corporation (QTX)
Competitive Landscape
Nautilus faces competition from established proteomics companies with existing commercial platforms and customer bases. Nautilus's advantage lies in its innovative single-molecule analysis technology, which could potentially offer superior performance. However, it must successfully bring its platform to market and demonstrate its advantages to gain market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: No historical revenue growth due to being pre-revenue.
Future Projections: Future growth is dependent on successful commercialization of their platform, with revenue projected to start in coming years (analyst estimates vary significantly).
Recent Initiatives: Continued development and refinement of their single-molecule protein analysis platform and securing partnerships.
Summary
Nautilus Biotechnology is an early-stage biotech company with a promising single-molecule proteomics platform. Its strength lies in its novel technology, but faces challenges in bringing it to market. The company needs to secure funding and demonstrate the superiority of its platform to gain traction. The current market dynamics and cash burn rate are serious concerns that could prevent it from becoming a competitor in the space.
Similar Companies
- SLGC
- OLK
- QTX
- PACB
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and analyst estimates, which are subject to change. This is not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nautilus Biotechnology Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2021-06-10 | Co-Founder, CEO, President, Secretary & Director Mr. Sujal M. Patel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 155 | Website https://www.nautilus.bio |
Full time employees 155 | Website https://www.nautilus.bio | ||
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system designed to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which are comprised of sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.